Currently Recruiting!
Who: Women ages 40-60, who are going through menopause and are experiencing depressive symptoms
What we are studying: We want to learn more about how allopregnanolone, the female hormone related to progesterone, affects the brain in perimenopausal women who are experiencing depression. We are studying this by giving women a form of allopregnanolone that is FDA approved to treat postpartum depression as part of a clinical trial involving treatment with allopregnanolone or placebo
Study participation includes:
- Being admitted to Brigham and Women’s Hospital for a 4-night inpatient stay on a research unit
- Receiving a 60-hour intravenous (IV) infusion of either allopregnanolone (given as the FDA-approved agent brexanolone) or placebo during the inpatient visit
- Completing up to 3 MRI brain scan visits, if eligible
Where: Brigham and Women’s Hospital, Boston MA.
Please note research study participation requires two trips to Brigham and Women’s Hospital. Parking valet vouchers are provided.
To see if you might be eligible to participate in this study, please complete this brief, online survey:
Click here for Pre-screen Survey
If you would like to speak with a Research Coordinator for this study, please email or call: mdelaney13@bwh.harvard.edu; 617-278-0689
Participants may be compensated up to $1,000 for their time. Parking/transportation for in-person visits will be reimbursed up to $25 per visit. Participants will not incur any study-related expenses.
